RxDoctor Payments Data

Christopher Perrone, MD

Neurology · Philadelphia, PANPI 1063827293

Payments from drug & device makers

$202,674in general payments, 2019–2025

Across 18 payments — averaging $11,260 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$189K
  • EMD Serono, Inc.$9K
  • Novartis$3K
  • Merck Kgaa$2K
$813in research payments, 2019–2025

Across 2 payments — averaging $406.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$813

What the payments were for

  • Consulting fees$11,86087%
  • Speaking & faculty fees$1,60012%
  • Food & beverage$1801%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen5$189,034
EMD Serono, Inc.7$9,200
Novartis5$2,840
Merck Kgaa1$1,600

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$202,674 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,847
Medicare patients
143
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab34$883,116
Kesimpta PenOfatumumab64$768,074
AubagioTeriflunomide38$352,353
TecfideraDimethyl Fumarate25$226,435
MayzentSiponimod21$203,671
FingolimodFingolimod Hcl25$50,356
Dalfampridine ErDalfampridine170$48,400
Glatiramer Acetate13$38,990
Teriflunomide17$33,603
MyrbetriqMirabegron45$24,192
Nurtec OdtRimegepant Sulfate14$22,667
GemtesaVibegron16$7,542
Baclofen144$2,507
Modafinil53$1,762
Lidocaine16$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$189,034$226,43525 claims
NovartisMayzent$2,840$203,67121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →